David Malcom Rodman - May 14, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Medical Officer
Signature: /s/ Adam Levy, Attorney-in-fact
Stock symbol: MLYS
Transactions as of: May 14, 2025
Transactions value $: -$173,774
Form type: 4
Date filed: 5/15/2025, 07:01 PM
Previous filing: May 13, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rodman David Malcom	Chief Medical Officer	150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR	/s/ Adam Levy, Attorney-in-fact	2025-05-15	0001672659

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Sale	-$174K	-11.4K	-9.63%	$15.29	107K	May 14, 2025	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.9100 to $15.7726. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.9100 to $15.7726. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.